A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model

Artificial Intelligence in Medicine

Volumn 46, Issue 2, 2009, Pages 119-130

  Smith, Wade P ^a   Doctor, Jason ^b   Meyer, Jürgen ^c   Kalet, Ira J ^a   Phillips, Mark H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

Bayesian network; Markov model; Multi attribute decision theory; Prostate cancer; Radiotherapy

Indexed keywords

CANCER PATIENTS; DECISION VARIABLES; DISTANT METASTASIS; HEALTH OUTCOMES; LOCAL TUMOR CONTROLS; MARKOV MODEL; MINIMAL TREATMENTS; MULTI-ATTRIBUTE DECISION THEORY; MULTIPLE OBJECTIVES; NORMAL TISSUES; OVER CURRENTS; PROBABILISTIC MODELS; PROSTATE CANCER; TREATMENT PLANS; TUMOR CONTROLS;

BAYESIAN NETWORKS; DECISION SUPPORT SYSTEMS; DISTRIBUTED PARAMETER NETWORKS; GAME THEORY; HEALTH RISKS; INFERENCE ENGINES; INTELLIGENT NETWORKS; MARKOV PROCESSES; PATIENT MONITORING; PHYSICAL THERAPY; RADIOTHERAPY; SPEECH ANALYSIS; TUMORS;

DECISION THEORY;

ANTIANDROGEN;

ARTICLE; BAYES THEOREM; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; DECISION SUPPORT SYSTEM; DISTANT METASTASIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; TREATMENT PLANNING; TREATMENT RESPONSE;

BAYES THEOREM; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MARKOV CHAINS; PATIENT CARE PLANNING; PROBABILITY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 67349242569     PISSN: 09333657     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.artmed.2008.12.002     Document Type: Article

References (43)

1. Haas O.C., Burnham K.L., and Mills J.A. Optimization of beam orientation in radiotherapy using planar geometry. Phys Med Biol 43 (1998) 2179-2193
2. Phillips M.H., Meyer J., Cho P.S., Kalet I.J., and Doctor J.N. Bayesian decision making applied to IMRT. In: Yi B., Ahn S., Choi E., and Ha S. (Eds). Proceedings of the 14th international conference on computers in radiotherapy (2004), Jeong Publishing 108-111
3. Meyer J., Phillips M.H., Cho P.S., Kalet I., and Doctor J.N. Application of influence diagrams to prostate intensity-modulated radiation therapy plan selection. Phys Med Biol 49 (2004) 1637-1653
4. Perez C.A. Prostate. In: Perez C.A., Brady L.W., Halperin E.C., and Schmidt-Ulrich R.K. (Eds). Principles and practices of radiation oncology. 4th ed (2004), Lippincott-Raven Publishers, Philadelphia, PA 1692-1762
5. A.S. for Therapeutic Radiology, O.C. Panel, Consensus statement: guidelines for PSA following radiation therapy, Int J Radiat Oncol Biol Phys 37;1997:1035-41.
6. Jensen F.V., and Nielson T.D. Bayesian networks and decision graphs (2007), Springer-Verlag, New York
7. Cowell R.G., Dawid A.P., Lauritzen A.L., and Spiegelhalter D.J. Probabilistic networks and expert systems (1999), Springer, New York
8. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095-1101
9. Horwitz E.M., Hanlon A.L., Pinover W.H., Anderson P.R., and Hanks G.E. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 92 (2001) 1281-1287
10. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 24 (1997) 103-110
11. Wang J.Z., and Li X.A. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med Phys 30 (2003) 34-40
12. Zelefsky M.J., Ben-Porat L., Scher H.I., Chan H.M., Fearn P.A., Fuks Z.Y., et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 23 (2005) 826
13. Vicini F.A., Kestin L.L., and Martinez A.A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 88 (2000) 2305-2318
14. Fiorino C., Sanguineti G., Cozzarini C., Fellin G., Foppiano F., Menegotti L., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 15 (2003) 953-962
15. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 8 (1985) 13-S19
16. Lyman J.T., and Wolbarst A.B. Optimization of radiation therapy. III. A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 13 (1987) 103-109
17. Kutcher G.J., and Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 16 (1989) 1623-1630
18. Rancati T., Fiorino C., Gagliardi G., Cattaneo G.M., Sanguineti G., Borca V.C., et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study. Radiother Oncol 73 (2004) 21-32
19. Peeters S.T., Hoogeman M.S., Heemsbergen A.A., Hart W.D., Koper P.C., and Lebesque J.V. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 66 (2006) 11-19
20. Söhn M., Yan D., Liang J., Meldolesi E., Vargas C., and Alber M. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys 67 (2007) 1066-1073
21. Cheung M.R., Tucker S.L., Dong L., de Crevoisier R., Lee A.K., Frank S., et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1059-1065
22. Beck J.R., and Pauker S.B. The Markov process in medical prognosis. Med Decis Making 3 (1983) 419-458
23. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 (1993) 322-338
24. Hunink M., and Glasziou P. Decision making in health and medicine (2001), Cambridge University Press, Cambridge
25. Period life table. http://www.ssa.gov/oact/stats/table4c6.html; 2004 [accessed 4.09.08].
26. Stewart S.T., Lenert L., Bhatnagar V., and Kaplan R.M. Utilities for prostate cancer health states in men aged 60 and older. Med Care 43 (2005) 347-355
27. Roach M., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., et al. Whole-pelvis, mini-pelvis, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation. Int J Radiat Oncol Biol Phys 66 3 (2006) 647-653
28. Karlsdóttir A., Muren L.P., Wentzel-Larsen T., and Dahl O. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys 70 (2008) 1478-1486
29. Sommers B.D., Beard C.J., D'Amico A.V., Dahl D., Kaplan I., Richie J.P., et al. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 110 (2007) 2210-2217
30. Horwitz E.M., Bae K., Hanks G.E., Porter A., Grignon D.J., Brereton H.D., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase iii trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 15 (2008) 2497-2504
31. Miften M.M., Das S.K., Su M., and Marks L.B. A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys 5 (2004) 1-14
32. Meyer R.R., Zhang Z.H., Goadrich L., Nazareth D.P., Shi L., and D'Souza W.D. A multiplan treatment-planning framework: a paradigm shift for intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1178-1189
33. Jain N.L., Kahn M.G., Drzymala R.E., Emami B.E., and Purdy J.A. Objective evaluation of 3-d radiation treatment plans: a decision-analytic tool incorporating treatment preferences of radiation oncologists. Int J Radiat Oncol Biol Phys 26 (1993) 321-333
34. Fleming C., Wasson J.H., Albertsen P.C., Barry M.J., and Wennberg J.E. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269 (1993) 2650
35. Bhatnagar V., Stewart S.T., Bonney W.W., and Kaplan R.M. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. Urology 63 (2004) 103-109
36. Konski A., Watkins-Bruner D., Feigenberg S., Hanlon A., Kulkarni S., Beck J.R., et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 408-415
37. Konski A., Speier W., Hanlon A., Beck J.R., and Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 25 (2007) 3603-3608
38. Lucas P.J., Boot H., and Taal B.G. Computer-based decision support in the management of primary gastric non-Hodgkin lymphoma. Methods Inform Med 3 (1998) 206-219
39. Galán S.F., Aguado F., Díez F.J., and Mira J. NasoNet modeling the spread of nasopharyngeal cancer with networks of probabilistic events in discrete time. Artif Intell Med 25 (2002) 247-264
40. Rouprêt M., Hupertan V., Yates D., Comperat E., Catto J., Meuth M., et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 101 11 (2008) 1448-1452
41. Lucas P.J., van der Gaag L.C., and Abu-Hanna A. Bayesian networks in biomedicine and health-care. Artif Intell Med 30 (2004) 201-214
42. Verduijn M., Peek N., Rosseel P.M., de Jonge E., and de Mol B.A. Prognostic Bayesian networks I: rationale, learning procedure, and clinical use. J Biomed Inform 40 6 (2007) 609-618
43. Pauker S.G., and Wong J.B. The influence of influence diagrams in medicine. Decis Anal 2 (2005) 238